Biotech is a very risky business. Many biotechnological products do not produce the desired results sequentially, while others cannot be recognized in the market. Of course, when a biotech product succeeds, investors can make a lot of money.
You can stay away from the roller coaster by looking for companies that have a stable track record, with growth prospects that are reasonable, not dramatic.
Despite the drama that is built into the biotechnology business, there are companies that go quietly and offer investors reliable returns. (To learn more, check out: Primer in the biotechnology sector.)
Celgene focuses on cancer and inflammatory diseases. The company not only develops its own products — it collaborates with other large manufacturers of medicines to bring products to the market.
Revenue has grown in recent quarters, while operating income has been steadily increasing. Celgene is a stable company, especially considering that the biotechnology sector carries a high risk.
Stocks began in 2019 with steady gains until April, but then returned those gains. In early June, stocks found support and began to grow again. After another fall in August, stocks continued their stable operation. Celgene may perform well in the last quarter of 2019. The company has financial expectations for the remainder of the year that exceed analysts’ estimates. (See Also: Celgene, Biogen prepare to break: technical view.)
Gilead Sciences, Inc. (GILD GILDGilead Sciences Inc73 46-0 47% Created with Highstock 4. 2.6)
Gilead has been growing at around 30% over five years. The company is a leader in the treatment of HIV infection and has a successful drug for the treatment of hepatitis C. Revenues are growing, and operating incomes have been growing over the past four years. Analysts and the company forecast profit growth until 2019 and will last until 2019.
A look at the stock chart shows that Gilead has been with a declining price channel since May 2019. Shares fell to the bottom at around $ 64, and then broke sharply rose at the end of June 2019. In early September, stocks had a major large-scale breakthrough, but have not succeeded since then. (For details, see below: Gilead, Amgen, and Biogen can raise biotechnology higher.)
Exelixis, Inc. (EXEL EXELExelixis Inc26. 25 + 2. 86% Created with Highstock 4. 2. 6)
Exelixis focuses on cancer treatment. It has anticancer drugs as well as kidney cancer treatments. The company regularly made positive surprises regarding profits. The management estimates that Exelixis will grow by more than 110% in 2019.
The stock had a breakthrough to start the year, and then began to form a base. He remained at this stage of consolidation in the first half of the year. At the end of June 2019, the stock market plummeted from the base, and despite falling at the end of September, it essentially continued to grow. Exelixis made a licensed deal with Takeda Pharmaceutical (TKPYY TKPYYTakeda Pharma28. 28-0. 14% Created with Highstock 4. 2. 6), which pleased investors, and its liver cancer drug is coming from trials soon. (See also: Exelixis, Takeda Ink $ 145M Cancer License Pact.)
Average volume: 3, 461, 224
Market cap: $ 7. 345 billion
P / E Ratio (TTM): 126. 21
EPS (TTM): $ 0. 20
Dividends and yield: N / A (N / A)
Enzo Biochem, Inc. (ENZ ENZEnzo Biochem Inc. 99 + 2. 78% Created with Highstock 4. 2. 6)
Enzo offers treatments for cancer, diabetes, cardiovascular disease, and infectious diseases. Stocks have been in an uptrend since March 2016, and he began to form a new base in December 2016. Shares began to grow from the beginning of March 2017 and have been rising since then. He had a second breakthrough on June 11, 2017. Now it is located on a new base, which began to form in late June.
Average volume: 190, 250
Market cap: $ 492.011 million
P / E Ratio (TTM): 14. 82
EPS (TTM): $ 0. 71
Dividends and yield: N / A (N / A)
AbbVie Inc. (ABBV ABBVAbbVie Inc92 .31 + 1. 42% Created with Highstock 4. 2. 6)
AbbVie is the creator of Humira, which refers to autoimmune problems. The company also has products for the treatment of leukemia and hepatitis C, as well as treatments that suppress HIV. AbbVie is involved in testosterone replacement procedures and has drugs for multiple sclerosis. Stocks have been in an uptrend since late April 2017. (For more details see: AbbVie Tops Q2 Earnings and earnings, undisclosed Outlook.)
Average volume: 6, 224, 303
Market Cap: $ 146. 05 billion
P / E Ratio (TTM): 22. 53
EPS (TTM): $ 4.07
Dividends and profitability: $ 2. 56 (2. 81%)
Investing is not a game of chance. Although the biotechnology sector carries a risk, you can still find reputable companies with reasonable growth prospects. All the companies on this list have experienced ups and downs in the industry and they look like they are ready to take first place in the remainder of 2